#United States #San Diego #IBD #Prifemilast #Apremilast

Prifemilast Shows Dramatic Effectiveness Over Apremilast in Phase 3 Psoriasis Study

In a landmark Phase 3 clinical trial held by cAMPfield Therapeutics and its partner Newsoara Biopharma, prifemilast, a novel oral medication, has demonstrated remarkable superiority to apremilast in treating adults suffering from moderate to severe plaque psoriasis. This trial showcased that prifemilast not only has a positive impact on psoriasis but also holds future promise for treating inflammatory bowel disease (IBD).

Phase 3 Trial Insights

In the head-to-head comparison, prifemilast at a dosage of 20 mg once daily nearly doubled the achievement rate of the PASI 75 response (which indicates at least a 75% reduction in the psoriasis area and severity index) in patients compared to apremilast at 30 mg taken twice a day. Specifically, 64.6% of participants on prifemilast achieved this benchmark compared to only 35.3% on apremilast. Furthermore, when examining the safety profiles, rates of serious adverse events and treatment discontinuation due to these events were comparable between both treatment groups, underscoring prifemilast's tolerability.

Long-term Efficacy and Safety

In a separate placebo-controlled Phase 3 study, prifemilast exhibited continued effectiveness, maintaining therapeutic responses across a 52-week period. This sustained improvement was evidenced as early as Week 2, revealing its potential as a long-lasting treatment option for psoriasis. With over a thousand participants in these trials, prifemilast has built a substantial safety database, enhancing confidence in its therapeutic viability.

Exploring Beyond Psoriasis

The implications of these results extend beyond just psoriasis treatment. As IBD, characterized by autoimmune-driven inflammation of the gastrointestinal tract, shares similar inflammatory pathways with psoriasis, prifemilast is now advancing into global Phase 2 trials focused on ulcerative colitis and Crohn’s disease. This progression represents an exciting avenue for patients who currently face limited effective treatment options for these chronic conditions.

Bill Gerhart, CEO of cAMPfield, expressed enthusiasm over the trial results, stating, "Outperforming apremilast head-to-head is a high bar, and prifemilast cleared it decisively on both co-primary endpoints, demonstrating its potential to be a best-in-class PDE4 inhibitor."

About the Drug Development

Prifemilast is a PDE4B inhibitor designed to mitigate anti-inflammatory activity while minimizing side effects linked to other PDE inhibitors. With its promising efficacy evidencing an enduring response and an acceptable safety profile, prifemilast can transform the treatment landscape for both psoriasis and IBD.

What's Next for Prifemilast?

The upcoming global trials for prifemilast will examine its efficacy in ulcerative colitis and Crohn’s disease, offering hope to millions affected by these conditions worldwide. The continuing collaboration between cAMPfield and Newsoara represents a significant investment in research that could lead to groundbreaking treatments.

In conclusion, the results of the recent trial highlight the comprehensive potential of prifemilast not only as a significant advancement in the treatment of psoriasis but also as a viable option for tackling other serious inflammatory diseases. As the healthcare community eagerly watches, further research will clarify its role in broader therapeutic applications.